EXCLUSIVE: BioRestorative Seeks Expanded FDA Approval For BRTX-100 Clinical Application, Engages Advisory Firm

BioRestorative Therapies Inc BRTX has entered into an agreement with Bruder Consulting & Venture Group, a full-service strategic advisory, to assist the company in seeking FDA approval for the expanded clinical application of BRTX-100.

BRTX-100 is BioRestorative's lead clinical candidate, a novel cell-based therapeutic engineered to target areas of the body with little blood flow.

BRTX-100 is currently being evaluated in connection with a Phase 2 clinical trial in chronic lumbar disc disease.

The 99-subject trial will evaluate the safety and preliminary efficacy of a single dose of BRTX-100, including specific release criteria of 40 million cells intradiscally injected into the nucleus of the lumbar disc.

EXCLUSIVE: BioRestorative To Receive Third US Patent For Metabolic ThermoStem Program.

"Finding the right partner such as BCVG is very meaningful to BioRestorative as they bring a tremendous amount of domain expertise in managing the regulatory pathway for cellular therapies. Additionally, we have the opportunity to leverage this musculoskeletal platform across other indications within the body. BCVG will assist us in choreographing this process, utilizing their deep industry insights and expertise within this sector," said Lance Alstodt, CEO of BioRestorative

Price Action: BRTX shares closed at $3.02 on Friday.